Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 131-138

  Vinholes, J ^a   Guo, C Y ^a   Purohit, O P ^a   Eastell, R ^a   Coleman, R E ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DEOXYPYRIDINOLINE; HYDROXYPROLINE; PAMIDRONIC ACID;

ACCURACY; ADULT; AGED; ARTICLE; BONE METASTASIS; CALCIUM CELL LEVEL; CALCIUM EXCRETION; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; DRUG EFFECT; FEMALE; HUMAN; HYPERCALCEMIA; KIDNEY TUBULE ABSORPTION; MAJOR CLINICAL STUDY; MALE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031032567     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.131     Document Type: Article

References (33)

1. Coleman R, Rubens R: The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66, 1987
2. Berenson J, Lichtenstein A, Knight R, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488-493, 1996
3. Conte P, Giannessi P, Mauriac L, et al: Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: A randomized, multicenter phase III trial. Ann Oncol 5:S41-44, 1994 (suppl 7)
4. Coleman R, Rubens R, Fogelman I: The bone scan flare following systemic therapy for bone metastases. J Nucl Med 29:1354-1359, 1988
5. Vogel CL, Schoenfelder J, Shemano I, et al: Worsening of bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 13:1123-1128, 1995
6. Downey S, Walls J, Eastell R, et al: Pyridinoline excretion can monitor bone metastases in breast cancer. Breast Cancer Res Treat 32:83, 1994 (abstr) (suppl 1)
7. Vinholes J, Eastell R, Coleman R, et al: Metabolic effects of pamidronate in patients with bone metastatic bone disease. Br J Cancer 73:1089-1095, 1996
8. Body J, Delmas P: Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 74:471-475, 1992
9. Pecherstorfer M, Hermann Z, Thiebaud D, et al: Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 14:268-276, 1996
10. Hanson DA, Weis MAE, Bollen AM, et al: A specific immunoassay for monitoring human bone resorption: Quantification of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251-1258, 1992
11. Bonde M, Qvist P, Christiansen C, et al: Applications of an enzyme immunoassay for a new marker of bone resorption (Cross-laps): Follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin End Metab 80:864-868, 1995
12. Robins SP, Woitge H, Hesley R, et al: Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643-1649, 1994
13. Blumsohn A, Naylor KE, Eastell R, et al: Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease. Clin Chem 41:1592-1598, 1995
14. Prestwood K, Pilbeam C, Delmas P, et al: The short-term effects of conjugated oestrogen on bone turnover in older women. J Clin Endocrinol Metab 79:366-371, 1994
15. Demers LM, Costa L, Chinchilli VM, et al: Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 41:1489-1494, 1995
16. Purohit OP, Kanis J, Coleman R, et al: Randomised double-blind comparison of single infusions of pamidronate or clodronate for hypercalcaemia of malignancy. Br J Cancer 72:1289-1293, 1995
17. Colwell A, Russell RGG, Eastell R: Factors affecting the assay of urinary 3-hydroxy pyridinium cross-links of collagen as markers of bone resorption. Eur J Clin Invest 23:341-349, 1993
18. Thurlimann B, Waldburger R, Senn HJ, et al: Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: A prospective randomized cross-over trial. Ann Oncol 3:619-623, 1992
19. Paterson AHG, Powles TJ, Kanis JA, et al: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65, 1993
20. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498, 1993
21. Sahni M, Guenther H, Fleisch H, et al: Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:204-211, 1993
22. Lowik CWGM, Van der Pluijm G, Bijvoet OLM: Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effects of a bisphosphonate. J Bone Miner Res 3:185-192, 1988
23. Boonenkamp PM, Van der Wee Pals, Bijvoet OLM, et al: Enhancement of the inhibitory action of APD on the transformation of the osteoclasts precursors into resorbing cells after dimethylation of the amino group. Bone Miner 2:29-42, 1987
24. Body J, Dumon J, Thirion M, et al: Circulating PTH-rP concentrations in tumor-induced hypercalcemia: Influence on the response to bisphosphonates and changes after therapy. J Bone Miner Res 8:701-706, 1993
25. Pecherstorfer M, Schiling T, Blind E, et al: Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab 78:1268-1270, 1994
26. Deacon AC, Hulme P, Hesp R, et al: Estimation of whole body bone resorption rate: A comparison of urinary hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis. Clin Chim Acta 166:297-306, 1987
27. Eyre DR, Koob TJ, Van Ness KP: Quantification of hydroxy-pyridinium cross-links in collagen by high performance liquid chromatography. Ann Biochem 137:380-388, 1984
28. Uebelhart D, Gineyts E, Delmas PD, et al: Urinary excretion of pyridinium cross-links: A new marker of bone resorption in metabolic bone disease. Bone Miner 8:87-96, 1990
29. Fujimoto D, Suzuki M, Inoue T, et al: Analysis of pyridinoline, a crosslinking compound of collagen fibres in human urine. J Biochem 94:1133-1136, 1983
30. Pecherstorfer M, Ludwig H, Zimmer-Roth I, et al: The diagnostic value of urinary pyridinium cross-links of collagen, alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80:97-103, 1995
31. Lipton A, Demers L, Seyedin S, et al: Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem 39:614-618, 1993
32. Garnero P, Christiansen C, Delmas P, et al: Different effects of bisphosphonate and oestrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 10:641-649, 1995
33. Garnero P, Shih W, Delmas P, et al: Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700, 1994